Esketamine Depression Research Study

3401 N Central Ave near Addison, Chicago IL

Description

Chicago Research Center is seeking candidates for a treatment-resistant depression research study. Skip the hassle of daily antidepressants with Spravato, a weekly esketamine nasal spray. This rapid-acting treatment is the only medication ever FDA-approved for treatment-resistant depression. Receive access to this highly coveted treatment free of charge, no insurance required, by enrolling in our study. Seeking Candidates who: - Are aged 18+ - Have tried and failed on at least 2 antidepressants in their lifetime (proof of med trials is required) - You may be eligible regardless of whether or not you're currently treating your depression with meds Take our brief survey to have a clinician reach out to you to see if you may qualify for the current studies: https://www.surveymonkey.com/r/QYT2NHT (you may have to copy and paste into web browser) Call with any questions: